Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the management of relapsed and refractory myeloma, with excellent outcomes and a tolerable safety profile. High dose chemotherapy with autologous hematopoietic stem cell transplantation (AHCT) is established as a mainstream of newly d...
| Hlavní autoři: | , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Frontiers Media S.A.
2024-03-01
|
| Edice: | Frontiers in Oncology |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1373548/full |